Economic Impact of Chronic Heart Failure Management in Today’s Cost-Conscious Environment

This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society describes the current status of mobile health (“mHealth”) technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self‐management are novel aspects of mHealth. The promises of predictive analytics but also operational challenges in embedding mHealth into routine clinical care are explored.

show abstract

“…Heart failure is widely prevalent, costly to manage, and degrades patient outcomes 215,216 . HF may trigger AF and ventricular arrhythmias.…”

Section: Comorbiditiesmentioning

confidence: 99%

2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals

Varma

Cygankiewicz

Turakhia

et al. 2021

Journal of Arrhythmia

Self Cite

View full text Add to dashboard Cite

show abstract

“…Heart failure is widely prevalent, costly to manage, and degrades patient outcomes (Benjamin et al, 2017, Albert & Estep, 2019 (Table 4) , Dickinson et al, 2018.…”

Section: Heart Failurementioning

confidence: 99%

2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals

Varma

Cygankiewicz

Turakhia

et al. 2021

Noninvasive Electrocardiol

Self Cite

View full text Add to dashboard Cite

This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/ Heart Rhythm Society/ European Heart Rhythm Association/ Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth") technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self‐management are novel aspects of mHealth. The promises of predictive analytics but also operational challenges in embedding mHealth into routine clinical care are explored.

show abstract

“…Considering that CHF care is extremely costly, new therapeutic approaches are urgently needed. 4 CHF has two distinct phenotypes: heart failure (HF) with reduced ejection fraction and HF with preserved ejection fraction (HFpEF). 5 These two phenotypes have completely different natural history, pathophysiological mechanisms, and underlying molecular processes 5,6 .…”

Section: What Are the Clinical Impplications?mentioning

confidence: 99%

Microbiome changes in patients with chronic heart failure with preserved ejection fraction correlate with fibrosis markers: Description of a Russian cohort

Novoselov

Kaburova

Pokrovskaya

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Chronic heart failure (CHF) affects approximately 26 million people worldwide. Nearly half of CHF patients develop heart failure with preserved ejection fraction (HFpEF), which is associated with myocardial hypertrophy and fibrosis. Although chronic inflammation was suggested as a critical factor contributing to fibrosis development, a new hypothesis of CHF pathogenesis suggested that altered gut microbiota contributes to leaky gut phenotype development and promotes a systemic inflammatory state. CHF patients have an altered gut microbiome. However, the effect of gut microbiota on fibrosis development in HFpEF patients is not yet known. Thus, this clinical study involving HFpEF patients (n = 47) and healthy volunteers (n = 43) intended to identify the correlations between microbiota changes and fibrosis markers in HFpEF patients. Methods We used 16S rRNA metagenomic sequencing to identify the microbiota changes in HFpEF patients. Myocardial fibrosis was quantified using T1 myocardial mapping by using cardiac magnetic resonance. We also assessed the levels of microbial metabolites—trimethylamin N-oxide (TMAO) and short-chain fatty acids (SCFAs)—and measured bloodstream miRNAs and cytokines. The gut microbiome functions were simulated using PICRUSt algorithm. Results The gut microbial communities of HFpEF patients were markedly different from those of healthy individuals. The abundance of Faecalibacterium, Prevotella, and Pseudomonas was significantly decreased, whereas that of Lachnoclostridium, Blautia, Haemophilus, Dorea, Peptococcus, and Tyzzerella was increased in HFpEF patients. These changes could have affected TMAO metabolism and SCFA production: TMAO and hydroxypyruvate levels were significantly higher, whereas isovaleric, methylbutyric, and propionic acids were significantly lower in HFpEF patients than in healthy individuals. The simulation with PICRUSt revealed that genes responsible for starch fermentation, SCFA production, and secondary bile acid metabolism were downregulated. Correlation analysis identified the involvement of microbiota changes and miRNAs 183-3p and 193b-3p. Conclusions Gut microbiome composition shifts in HFpEF patients impair biochemical functions, increase TMAO production, and decrease SCFA biosynthesis. The significant decrease in Faecalibacterium could have the most prominent effect on the host physiology. However, this needs to be determined by conducting experiments on animal models, because the mechanism by which the microbiota is associated with cardiac fibrosis development is not yet known.

show abstract

Economic Impact of Chronic Heart Failure Management in Today’s Cost-Conscious Environment

Cited by 16 publications

References 75 publications

2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals

2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals

2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals

Microbiome changes in patients with chronic heart failure with preserved ejection fraction correlate with fibrosis markers: Description of a Russian cohort

Contact Info

Product

Resources

About